Axonis Therapeutics Inc. has disclosed dual specificity mitogen-activated protein kinase kinase (MAP2K7; MKK7) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, spinal cord injury, multiple sclerosis, neurodegeneration, lysosomal storage, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease, among others.